The Pharmacy Times® C. Difficile Resource Center is a comprehensive resource for clinical news and expert insights on issues related to Clostridium difficile, a bacteria that causes colitis, a serious inflammation of the colon.
June 17th 2025
Clostridioides difficile (C difficile) represents a serious public health threat, with pharmacists and advocacy organizations playing critical roles in prevention, education, and management.
Prolonged β-Lactam Infusions and Patients Outcomes: Insights From the BLING III Trial
July 28th 2024The BLING III trial investigated continuous vs intermittent β-lactam antibiotic infusions in critically ill patients with sepsis, finding no significant difference in 90-day mortality but suggesting potential benefits in clinical cure rates.
Read More
Impact of Pharmacist-Led Initiatives on Health Care–Associated Clostridioides difficile Rates
March 14th 2024Antimicrobial stewardship efforts focusing on accurate penicillin allergy histories, β-lactam cross-reactivity education, and guideline-driven narrow-spectrum prescribing may help sustainably decrease health care–associated Clostridioides difficile infection rates.
Read More
Recurrent C difficile Infection Prevention: Efficacy and Administration of Fecal Microbiota Therapy
January 31st 2024Sharon Rimon, NP, shares insights on the rectal administration of fecal microbiota therapy, highlighting its efficacy, ease of adoption in clinical practice, and benefits for patients.
Read More
Managing Recurrent C difficile Infections: Past, Present, and Future
Since 2000, as the number of CDIs has surged, morbidity and mortality also have increased.
Read More
Navigating C. Diff During the COVID-19 Pandemic, The Impact of Antibiotic Usage and Surgeries
December 14th 2023Feldman details her experience with C. diff, how the COVID-19 pandemic slowed the timeline of care, and how her surgical history and the use of antibiotics played into the disease’s onset.
Watch
Rebyota Found Safe, Effective in Preventing Recurring Clostridioides Difficile Infection
October 16th 2023Treatment-emergent adverse events associated with Rebyota for Clostridioides difficile infection were more prevalent in those with renal comorbidities than in those without and were moderate in severity as well as related to pre-existing conditions.
Read More